Session II: Implementation of BCS and Biowaiver for Class 3 Drugs
There are an increasing number of successful biowaiver applications, but faster progress could be made if there were international harmonization and the implementation barrier of the perception of risk for project delays could be removed. BCS-based Biowaiver case studies were presented by several industry representatives. Gordon Amidon, University of Michigan, and Salomon Stavchansky, University of Texas at Austin, debated the issue of Biowaivers for Class 3 drugs. One of the points made was that within BCS Class 3, the "risk" of a biowaiver may vary significantly depending on the magnitude of the "poor" P (permeability). Thus, risk analysis techniques may be pertinent to deciding whether or not a BCS 3 biowaiver could be granted. Excipient effects are often cited as a possible source of influence on BA not predicted by dissolution testing, yet there are few examples of common excipients used at typical levels that actually influence BABE in any significant way. This is a potential area for further research. For example, the "dose-response" effect of excipients could be systematically studied. Another point raised was that there are examples supporting the fact that differences in dissolution of Class 1 compounds with rapid dissolution (within 30 minutes) do not affect C max and AUC-possibly there could be a relaxation of the criteria by excluding the requirement for f 2 test for Class 1 drugs with complete dissolution within 30 minutes. An unresolved issue was how to handle (from a regulatory standpoint) situations where the formulation may change the BCS class (e. g., from 2 to 1). Since the BCS Class is pegged to the chemical entity, can the regulatory framework accommodate this "formulation" effect? In addition, industry and various individual companies have indicated that a significant majority of new chemical entities are BCS Class 2. Thus, the focus should be on Class 2 rather than on extensions to Class 3, which occur to a relatively low extent. For example, should the regulators be looking at relaxing the Class 1 criteria in a way that would include more Class 2 drugs that "nearly miss" Class 1?
Session III: Bioequivalence for Highly Variable and GI Locally Active Drugs
Charlie DiLiberti of Barr Labs stressed the importance of simulations and suggested that C max variance has little effect on steady state conditions. AUC can have a significant effect, leading him to conclude that C max and AUC are a better measure of bioequivalence for highly variable drugs. Barbara Davit of FDA pointed out that about 10% of the BE submissions are for highly variable drugs; of these, the variability in 70% is attributed to the disposition Session IV: Biorelevant Dissolution and BCS Future Development Paul Dickinson and Bertil Abrahamsson, both from AstraZeneca, addressed the issue of clinical relevance of dissolution testing in quality by design (QbD). The major point they made was that dissolution testing should be applicable to assure desired clinical performance for a wide range of drugs in QbD, based on BCS considerations and specific product knowledge. Failure to establish a classical IVIVC could be a successful outcome of an IVIV study in context of QbD if all variants (i. e., side batches) produce the same exposure. Variants should be assessed via an in vivo biostudy, and generation of variants should be done during development for the highest risk factor impacting dissolution. Peter Langguth of the Johannes Gulenberg-University Mainz recommended that simulations and modeling may help identity BCS Class 2 biowaiver candidates. There is a need for robust and predictive dissolution methods, combined with additional validation of the simulations. Lawrence Yu of FDA gave a summary of possible revisions to the BCS Class boundaries. A probable revision will change the pH range from 1-7.5 to 1-6.8 for defining high solubility. Another would be to reduce the permeability boundary from 90% to 85%. There may be change in the rapid dissolution criteria from >85% in 30 minutes to >85% in 45 minutes in the dissolution media of 0.1 N HCl, pH 4.5, and pH 6.8 buffers. For Class 2 drugs that are weak acids having low solubility at low pH and high solubility at high pH, there are concerns about the predictability of in vitro dissolution to in vivo, because there may be incomplete dissolution and the excipients may have an effect on solubility and dissolution. He said that biowaiver extensions to BCS Class 3 drugs were likely, although there is still the concern of excipient effect on permeability (e. g., absorptive transporters and GI motility). He spoke of the two different roles of dissolution. There is the dissolution for in vivo performance, which would be a biorelevant dissolution test that correlates with the in vivo dissolution. This would be a one-time test to provide a baseline for product performance-this is the test that biowaivers would rely on. Then there is the dissolution test for quality control that would be a product-specific test. This test could be the same as the in vivo performance dissolution test. Dissolution conditions would emphasize reproducibility and detection of product changes and would not be constrained to mimic in vivo conditions. The acceptance criteria would be to ensure consistency of the batches. He pointed out that the WHO has proposed a simplified test for solid oral dosage forms that contain highly soluble drugs that would use the paddle at 75 rpm, 500 mL, 37 °C, 30-min sample, and a dissolution media using simulated intestinal fluid at pH 6.8. The specification would be g85% released in 30 minutes.
